Maria Hordinsky Selected Research

Alopecia Areata

1/2022	Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
1/2022	Two Phase 3 Trials of Baricitinib for Alopecia Areata.
1/2022	Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study.
1/2021	A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS).
7/2020	The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata.
10/2018	High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.
5/2016	Molecular signatures define alopecia areata subtypes and transcriptional biomarkers.
6/2015	Alopecia areata update.
7/2014	Low-dose interleukin 2 to reverse alopecia areata.
7/2014	Alopecia areata: an evidence-based treatment update.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Hordinsky Research Topics

Disease

13	Alopecia Areata 01/2022 - 01/2004
7	Alopecia (Baldness) 01/2022 - 12/2006
3	Acne Vulgaris 01/2022 - 09/2002
3	Autoimmune Diseases (Autoimmune Disease) 06/2015 - 01/2004
1	Hair Diseases 01/2022
1	Mycosis Fungoides 01/2019
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2019
1	X-Linked Keratosis Follicularis Spinulosa Decalvans 11/2015
1	Inflammation (Inflammations) 03/2013
1	Infections 08/2010
1	Blister (Bulla) 08/2010
1	Epidermolysis Bullosa Dystrophica (Dystrophic Epidermolysis Bullosa) 08/2010
1	Cardiomyopathies (Cardiomyopathy) 08/2010
1	Pruritus (Itching) 08/2010
1	Dermatitis 08/2010
1	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2009
1	Vitiligo 01/2004
1	Thyroiditis 01/2004

Drug/Important Bio-Agent (IBA)

2	Janus KinasesIBA 01/2022 - 01/2022
2	SaltsIBA 01/2022 - 11/2009
2	Biomarkers (Surrogate Marker)IBA 05/2016 - 03/2013
1	CytokinesIBA 01/2022
1	Janus Kinase InhibitorsIBA 01/2022
1	Bimatoprost (Lumigan)FDA Link 01/2022
1	tofacitinibIBA 01/2022
1	baricitinibIBA 01/2022
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022
1	HDL CholesterolIBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	Brentuximab VedotinIBA 01/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2018
1	Substance PIBA 11/2015
1	Interleukin-2 (IL2)IBA 07/2014
1	salicylhydroxamic acid (SHAM)IBA 04/2014
1	Collagen Type VIIIBA 08/2010
1	pimecrolimus (Elidel)FDA Link 08/2010
1	Carrier Proteins (Binding Protein)IBA 07/2010
1	LigandsIBA 07/2010
1	Natural Killer Cell ReceptorsIBA 07/2010
1	Alefacept (Amevive)FDA Link 11/2009
1	Biological ProductsIBA 11/2009
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2008
1	Propylene Glycol (1,2 Propanediol)FDA LinkGeneric 11/2007
1	Minoxidil (Rogaine)FDA LinkGeneric 11/2007
1	Dihydrotestosterone (Androstanolone)IBA 12/2006
1	Dutasteride (Avodart)FDA Link 12/2006
1	Finasteride (Propecia)FDA LinkGeneric 12/2006
1	Cholestenone 5 alpha-Reductase (5 alpha-Reductase)IBA 03/2004
1	Minocycline (Cyclops)FDA LinkGeneric 03/2004
1	5-alpha Reductase InhibitorsIBA 03/2004
1	Immunomodulating AgentsIBA 01/2004
1	NeuropeptidesIBA 01/2004
1	AutoantibodiesIBA 01/2004
1	Oral ContraceptivesIBA 09/2002
1	Levonorgestrel (Plan B)FDA LinkGeneric 09/2002
1	AndrogensIBA 09/2002
1	Ethinyl Estradiol (Estinyl)FDA LinkGeneric 09/2002

Therapy/Procedure

5	Therapeutics 01/2021 - 01/2004
1	Lasers (Laser) 04/2014
1	Transplantation 08/2010
1	Drug Therapy (Chemotherapy) 08/2010
1	Stem Cell Transplantation 08/2010
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 08/2010